Stock Research for ABIO

ABIO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABIO Stock Chart & Research Data

The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABIO Due diligence Resources & Stock Charts

The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABIO Detailed Price Forecast - CNN Money CNN View ABIO Detailed Summary - Google Finance
Yahoo View ABIO Detailed Summary - Yahoo! Finance Zacks View ABIO Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABIO Trends & Analysis - Trade-Ideas Barrons View ABIO Major Holders - Barrons
NASDAQ View ABIO Call Transcripts - NASDAQ Seeking View ABIO Breaking News & Analysis - Seeking Alpha
Spotlight View ABIO Annual Report - CompanySpotlight.com OTC Report View ABIO OTC Short Report - OTCShortReport.com
TradeKing View ABIO Fundamentals - TradeKing Charts View ABIO SEC Filings - Bar Chart
WSJ View Historical Prices for ABIO - The WSJ Morningstar View Performance/Total Return for ABIO - Morningstar
MarketWatch View the Analyst Estimates for ABIO - MarketWatch CNBC View the Earnings History for ABIO - CNBC
StockMarketWatch View the ABIO Earnings - StockMarketWatch MacroAxis View ABIO Buy or Sell Recommendations - MacroAxis
Bullish View the ABIO Bullish Patterns - American Bulls Short Pains View ABIO Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABIO Stock Mentions - StockTwits PennyStocks View ABIO Stock Mentions - PennyStockTweets
Twitter View ABIO Stock Mentions - Twitter Invest Hub View ABIO Investment Forum News - Investor Hub
Yahoo View ABIO Stock Mentions - Yahoo! Message Board Seeking Alpha View ABIO Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABIO - SECform4.com Insider Cow View Insider Transactions for ABIO - Insider Cow
CNBC View ABIO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABIO - OTC Markets
Yahoo View Insider Transactions for ABIO - Yahoo! Finance NASDAQ View Institutional Holdings for ABIO - NASDAQ


Stock Charts

FinViz View ABIO Stock Insight & Charts - FinViz.com StockCharts View ABIO Investment Charts - StockCharts.com
BarChart View ABIO Stock Overview & Charts - BarChart Trading View View ABIO User Generated Charts - Trading View




Latest Financial News for ABIO


ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Posted on Wednesday November 14, 2018

WESTMINSTER, Colo., Nov. 14, 2018 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.


GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions
Posted on Monday November 12, 2018

AF detection by implanted Medtronic devicesSimilar trends for benefit in favor of Gencaro compared to active comparator for AF risk reduction observed by continuous monitoring.


ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
Posted on Monday November 05, 2018

Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 --  ARCA biopharma,.


Westminster biotech company receives second extension on delisting notice from Nasdaq
Posted on Wednesday October 10, 2018

ARCA Biopharma, a Westminster biotech company, has been given an additional 180 days to regain compliance with Nasdaq’s $1 per share minimum bid price requirement, according to an SEC form filed Tuesday. “Our Nasdaq listing is obviously very important to the company and our shareholders, so we are very focused on regaining compliance with the Nasdaq minimum closing bid price continued listing requirement,” Derek Cole, the company’s investor relations leader, said in an email. “The additional 180-day compliance period affords ARCA the opportunity to potentially regain compliance.” ARCA Biopharma is the 12th largest biotechnology/biosciences company in Colorado as ranked by number of employees, according to Denver Business Journal research.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.